Compare
Zeo ScientifiX, Inc. vs DBV Technologies S.A. vs Prime Medicine, Inc. vs Fate Therapeutics Inc
| Latest fiscal year | Zeo ScientifiX, Inc. ZEOX | DBV Technologies S.A. DBVT | Prime Medicine, Inc. PRME | Fate Therapeutics Inc FATE |
|---|---|---|---|---|
| Year ended | 2025-10-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.20M | $5.64M | $4.63M | $6.65M |
| Revenue growth (YoY) | +12.5% | +35.8% | +55.3% | -51.2% |
| Gross margin | 82.1% | n/a | n/a | n/a |
| Operating margin | -103.6% | n/m | n/m | n/m |
| Net margin | -106.2% | n/m | n/m | n/m |
| Net income | -$5.52M | -$146.95M | -$201.14M | -$136.31M |
| EPS (Diluted) | -$0.86 | -$1.05 | -$1.35 | -$1.15 |
| Operating cash flow | -$718.0K | -$121.18M | -$162.56M | -$106.08M |
| Free cash flow | -$741.0K | -$121.71M | -$167.09M | -$112.04M |
| Cash & equivalents | n/a | $194.17M | $63.03M | $46.63M |
| Total assets | $1.53M | $233.72M | $342.73M | $318.94M |
| Total liabilities | $2.95M | $64.95M | $221.87M | n/a |
| Shareholders' equity | -$1.42M | $168.77M | $120.87M | $207.18M |
| Return on year-end equity | n/a | -87.1% | -166.4% | -65.8% |
| Shares outstanding | 6.75M | n/a | 180.51M | 115.36M |
Revenue, most recent five fiscal years
| Fiscal year | Zeo ScientifiX, Inc. | DBV Technologies S.A. | Prime Medicine, Inc. | Fate Therapeutics Inc |
|---|---|---|---|---|
| Latest | $5.20M Ended 2025-10-31 | $5.64M Ended 2025-12-31 | $4.63M Ended 2025-12-31 | $6.65M Ended 2025-12-31 |
| 1 year earlier | $4.62M Ended 2024-10-31 | $4.15M Ended 2024-12-31 | $2.98M Ended 2024-12-31 | $13.63M Ended 2024-12-31 |
| 2 years earlier | $4.56M Ended 2023-10-31 | $15.73M Ended 2023-12-31 | $0 Ended 2023-12-31 | $63.53M Ended 2023-12-31 |
| 3 years earlier | $6.49M Ended 2022-10-31 | $4.84M Ended 2022-12-31 | $0 Ended 2022-12-31 | $96.30M Ended 2022-12-31 |
| 4 years earlier | $5.60M Ended 2021-10-31 | $5.71M Ended 2021-12-31 | $0 Ended 2021-12-31 | $55.85M Ended 2021-12-31 |